Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 67th American Society of Hematology (ASH) Annual Meeting and Exposition took place on 6 - 9 December, 2025, in Orlando, FL, and online. This is the largest hematology event of the year, bringing together experts from around the world to discuss the latest advances.
View all videos

ASH 2025

The 67th ASH Annual Meeting and Exposition
06–09 December 2025 | Orlando, FL

ASH 2025

The 67th ASH Annual Meeting and Exposition
06–09 December 2025 | Orlando, FL
The 67th American Society of Hematology (ASH) Annual Meeting and Exposition took place on 6 - 9 December, 2025, in Orlando, FL, and online. This is the largest hematology event of the year, bringing together experts from around the world to discuss the latest advances.
View all videos

Latest Videos

View all videos
1:52
Ven+FluBu2 with PTCy/Tac/MMF RIC transplant followed by Ven/Aza maintenance for high-risk MDS/AML
H. Moses Murdock • 5 Dec 2025
6:23
Phase Ib study of bleximenib plus venetoclax in AML with KMT2A or NPM1 alterations
Jenny O'Nions • 15 Dec 2025
1:11
FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML
Sangeetha Venugopal • 7 Dec 2025
1:28
The potential of bispecific T-cell engagers targeting FLT3 in AML
Mohammad Maher Abdul-Hay • 7 Dec 2025

Lymphoma

View all
2:07
Follicular Lymphoma Foundation: research mission, biomarkers, and global collaboration
Mitch Smith • 6 Dec 2025
2:09
Real-world ibrutinib plus venetoclax in frontline CLL/SLL: REALITY-WW and REALITY-2 outcomes
Paolo Ghia • 5 Dec 2025

Multiple Myeloma

View all
8:27
Optimal ferritin threshold to diagnose IEC-HS following CAR T-cell therapy in R/R myeloma
Lekha Mikkilineni • 17 Dec 2025
4:18
MRD trajectory and prognosis in t(11;14) multiple myeloma treated with quadruplet therapy and ASCT
Luciano Costa • 16 Dec 2025

CLL

View all
2:48
AMPLIFY trial: how prognostic mutations impact outcomes with acalabrutinib-venetoclax in CLL
Paolo Ghia • 5 Dec 2025
2:09
Real-world ibrutinib plus venetoclax in frontline CLL/SLL: REALITY-WW and REALITY-2 outcomes
Paolo Ghia • 5 Dec 2025

AML

View all
1:52
Ven+FluBu2 with PTCy/Tac/MMF RIC transplant followed by Ven/Aza maintenance for high-risk MDS/AML
H. Moses Murdock • 5 Dec 2025
6:23
Phase Ib study of bleximenib plus venetoclax in AML with KMT2A or NPM1 alterations
Jenny O'Nions • 15 Dec 2025

MPNs

View all
1:03
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
Andrew Lane • 6 Dec 2025
3:26
Ruxolitinib plus CDK4/6 inhibitor abemaciclib in previously treated myelofibrosis: Phase I results
Jan Bewersdorf • 16 Dec 2025

ALL

View all
1:37
Patient-informed CRISPR screening reveals gene targets to improve CAR T-cell efficacy
Joseph Melenhorst • 5 Dec 2025
1:03
Exploring CD83 CARs as an approach to overcome CD19 antigen loss in B-cell malignancies
Marco Davila • 7 Dec 2025

MDS

View all
1:52
Ven+FluBu2 with PTCy/Tac/MMF RIC transplant followed by Ven/Aza maintenance for high-risk MDS/AML
H. Moses Murdock • 5 Dec 2025
1:03
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
Andrew Lane • 6 Dec 2025

Non-Malignant

View all
2:23
Non-opioid and integrative strategies for pain management during VOC in SCD
Claudia Morris • 6 Dec 2025
2:12
Improving equity in pain management for SCD
Daniel Sop • 6 Dec 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals